AstraZeneca ((AZN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: The HER-TEMPO study, officially titled ‘Real World Study of TrEatment Discontinuations and Modifications for Patients With HER2+ and HER2-low Metastatic Breast Cancer On Trastuzumab Deruxtecan,’ aims to evaluate real-world treatment outcomes of Trastuzumab Deruxtecan (T-DXd) in Canada. This study is significant as it provides insights into the effectiveness of T-DXd in routine care settings for patients with HER2-positive and HER2-low metastatic breast cancer.
Intervention/Treatment: The study focuses on Trastuzumab Deruxtecan, a drug used to treat patients with HER2-positive and HER2-low metastatic breast cancer. It is administered as part of routine clinical practice, providing real-world data on its impact.
Study Design: This observational study follows a cohort model, where patients are observed in a real-world setting without any intervention model or masking. The primary purpose is to gather data on treatment discontinuations and modifications.
Study Timeline: The study began on April 3, 2024, and was completed with the last update submitted on October 14, 2025. These dates are crucial as they mark the progress and completion of data collection, providing timely insights into treatment outcomes.
Market Implications: The completion of the HER-TEMPO study could positively influence AstraZeneca’s stock performance by demonstrating the real-world effectiveness of T-DXd, potentially boosting investor confidence. As the study confirms the drug’s utility in routine settings, it may also impact competitors in the oncology market, emphasizing the importance of real-world data in treatment evaluation.
The study is completed, with further details available on the ClinicalTrials portal.